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We have used ion mobility-mass spectrometry combined with molecular modeling for the
separation and configurational analysis of three low-molecular-weight isomeric organoru-
thenium anticancer complexes containing ortho-, meta-, or para-terphenyl arene ligands. The
isomers were separated using ion mobility based on traveling-wave technology and the
experimentally determined collision cross sections were compared to theoretical calculations.
Excellent agreement was observed between the experimentally and theoretically derived
measurements. (J Am Soc Mass Spectrom 2009, 20, 1119–1122) © 2009 American Society for
Mass SpectrometryThe application of electrospray ionization (ESI)mass spectrometry (MS) to organometallic chemis-try and its development toward the characteriza-
tion of organometallic species has been the focus of
previous studies [1–3]. ESI is a gentle ionization technique,
capable of transferring preformed ions from solution into
the gas phase, and has been used in previous investiga-
tions of the interaction of organometallic-based anticancer
drugs and biomolecules [4, 5]. The platinum-based drug,
cisplatin [cis-diamminedichloridoplatinum(II)], for exam-
ple, falls into this category and is one of the leading
drugs used in the fight against cancer. DNA is a
potential target for many metal-based anticancer drugs
and distortions of DNA structure often correlate with
anticancer activity. Other metal-based anticancer drugs,
such as those based on ruthenium, are being developed
as alternative treatments to combat cancer. In particu-
lar, the aim is to widen the spectrum of anticancer
activity, reduce unwanted side effects, and avoid cross-
resistance with cisplatin and related drugs. Insights into
the physical size and shape of these novel Ru-based
drugs are important for elucidation of structure–
activity relationships and for optimizing key interac-
tions such as intercalation into DNA [6, 7]. Here we
explore three novel isomeric Ru-based anticancer drugs
using a combined ion mobility and mass spectrometry
(IM-MS) approach.
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doi:10.1016/j.jasms.2009.02.016As a stand-alone technique, MS cannot separate
isomeric species or provide bulk structural conforma-
tional information. However, IM has the ability to
rapidly separate isomeric species (on the MS acquisition
timescale) based on differences in their collision cross
sections (CCSs; physical size and shape) in the gas
phase, thus providing specific information on ionic
configuration [8–11]. The combination of IM with MS
provides an extremely powerful analytical tool.
To investigate the possible benefits of the IM-MS
technique, an instrument that is based around “traveling-
wave” (T-wave) mobility separation [12–14] has been
used for the first time to analyze a mixture of three
low-molecular-weight isomeric ruthenium terphenyl
anticancer complexes (m/z 427.1 based on 102Ru, labeled
1, 2, and 3 in Figure 1a). The study has allowed us to
probe the individual differences in shape in an attempt
to correlate them with differences in anticancer activity.
Molecular modeling was also used to generate a range
of possible structures and the theoretical CCSs for these
structures were calculated for comparison with experi-
mentally derived T-wave values. Excellent agreement
was observed between the experimentally and theoret-
ically derived CCS measurements.
Experimental
Preparation of Samples for IM-MS
Complexes 1, 2, and 3 (Figure 1a) were dissolved in
methanol to a concentration of 1 ng/L (2 M) before
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1120 WILLIAMS ET AL. J Am Soc Mass Spectrom 2009, 20, 1119–1122infusion at 5 L/min into the source of the mass
spectrometer. (See Section S1 in the supplementary
material, which may be found in the electronic version
of this article.)
Hybrid Quadrupole/Ion Mobility/OA-ToF
MS Instrumentation
Experiments were performed using a Waters (Manches-
ter, UK) Synapt HDMS (high-definition mass spectrom-
eter) instrument. This instrument, described in detail
elsewhere [12], has a hybrid quadrupole/ion mobility/
orthogonal acceleration time-of-flight (OA-ToF) geom-
etry. Ions are accumulated and periodically released
into the mobility T-wave cell, where they separate
according to their mobility through action of a contin-
uous train of transient voltage pulses (traveling waves).
Mobility spectra are obtained by sequentially recording
200 ToF mass spectra following the release of the ion
packet into the mobility cell. The instrument was oper-
ated in electrospray positive-ion mode with a capillary
voltage of 3.0 kV. The mobility T-wave cell was oper-
ated at 2.1 mbar of nitrogen with a wave velocity of 300
m/s and wave height of 28.4 V for optimal separation of
the isomeric terphenyl complexes. A wave height of 20
V was used for optimal separation of the HCl neutral
loss species. Data acquisition and processing were car-
ried out using MassLynx (V4.1, Waters) software sup-
Figure 1. (a) The organometallic terphenyl ruthenium-based
anticancer complexes analyzed in this study and (b) the ESI mass
spectrum of a 1 ng/L (methanol) solution of complex 1.plied with the instrument.The approach to calculation of collision cross-section
values from the T-wave mobility device is explained in
Section S2 of the supplementary material.
Computation
The coordinates obtained from X-ray crystallographic
measurements were used for molecular dynamics sim-
ulations of more than 170,000 bimolecular collisions
between the molecular ion and He. These simulations
were used for generation of the lowest energy confor-
mation of the isomeric species. Initial He positions were
selected at random from a spherical shell centered on
the molecular ion and inner radius of 20 Å; atomic
velocities were selected at random from a Boltzmann
distribution corresponding to 298 K and a drift velocity
of 40 m/s (the average drift velocity in the experiments)
added to all atoms in the molecular ion. The molecular
ion was modeled using the CHARMs force field, in-
cluding all intramolecular degrees of freedom [16] with
He/molecular ion potentials taken from MOBCAL [17].
Simulations were implemented in DL_POLY [18] using
a 0.5-fs time step, the NVE ensemble, and no periodic
boundaries. CCSs were estimated using the open
source software program MOBCAL [17, 19]. Briefly, the
MOBCAL output is based on three different models,
which calculate the theoretical collisional cross section
of any molecule possessing a three-dimensional coordi-
nate file. These models are the projection approximation
(PA), exact hard sphere scattering (EHSS), and the
trajectory method (TM) [19]. The values obtained from
the three MOBCAL algorithms were then compared to
the T-wave–derived CCSs.
Results and Discussion
Isomeric terphenyl complexes of the type [(6-arene)
Ru(en)Cl], where the arene is para- (1), ortho- (2), or
meta-terphenyl (3) (p-, o-, or m-terp; Figure 1a) were
synthesized to investigate the effect on cytotoxicity of
the additional phenyl ring in comparison to biphenyl
(bip) complexes that we have previously studied in
detail [20, 21]. See Section S3 in the supplementary
material for further discussion.
Isomeric complexes 1, 2, and 3 were detected at m/z
427.1 (Figure 1b) corresponding to [M]. This mass
spectrum is representative of the three complexes under
the instrumental parameters used. The base peak in
each of the mass spectra corresponded to the neutral
loss of HCl at m/z 391.1. The mobility spectrum ob-
tained for m/z 427.1 from a mixture of complexes 2 and
1 showed distinct peaks with a 0.55-ms difference in
drift times (4.17 ms for 2 and 4.72 ms for 1; Figure 2b).
A slightly smaller difference of 0.5 ms was observed for
the mixture of 3 and 1 (4.22 ms for 3 and 4.72 ms for 1;
Figure 2c). With all three isomeric complexes mixed
together, 2 and 3 merged into one peak with drift time
centered around 4.22 ms. In Figure 2d, the drift time for
complex 2 alone (dashed line) is compared with the
for C
1121J Am Soc Mass Spectrom 2009, 20, 1119–1122 ORGANOMETALLIC ANTICANCER COMPLEXES: IM-MSdrift time of the mixture of 3 and 1 (solid line), high-
lighting the small but reproducible difference in arrival
time of complexes 2 and 3. These data show that it is
possible to separate a mixture of 1 and 3 or a mixture of
1 and 2, although similarities in conformation (shape) of
2 and 3 would render them difficult to separate using
the present ion mobility approach.
The difference in conformation of 1 (more elongated)
compared with that of 2 and 3 (more compact) corre-
lates with the different (increased) anticancer activity of
1 compared with the other two complexes [15]. See
Section S3 of the supplementary material for further
discussion. The drift times for each of the molecular
ions of the three isomeric complexes were converted
into CCS values as described in Section S2 of the
supplementary material and references therein, as
shown in Table 1. Table 1 shows the experimentally
derived CCS values for the [M  HCl] species. The
overlaid mobility spectrum obtained for m/z 391.1 for
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Table 1. Comparison of the CCS values of complexes 1–3
obtained using T-wave ion mobility measurements and
MOBCAL calculations
Complex
[M] calculated CCS (Å2)
T-Wave
( 0.5%)
MOBCAL
Projection
Approx.
MOBCAL
Trajectory
Method
MOBCAL
Exact Hard
Sphere
1 120.6 121.5 121.3 (7.3%) 130.0
2 113.0 112.2 112.9 (3.5%) 121.8
3 113.6 116.1 117.2 (4.7%) 125.1
Following loss of HCl [M  HCl]
1 115.3 119.3 118.1 (8.2%) 126.7
2 106.6 109.3 108.2 (3.6%) 117.7.00
Tim
(
bratio
s. A
2 an
plex
differ
. (No3 110.0 114.3 114.9 (4.7%) 122.4
1122 WILLIAMS ET AL. J Am Soc Mass Spectrom 2009, 20, 1119–1122compared with a difference of only 0.05 ms for the
respective isomeric [M] ions detected at m/z 427.1.
Upon molecular modeling visualization of the HCl
neutral loss species, it was observed that the loss of a
chlorine atom from the parent terphenyl complex had a
dramatic effect on conformation and is reflected in the
observed drift times and the T-wave–derived CCSs.
No crystal structures have been obtained for the
[M  HCl] isomers because such coordinatively un-
saturated complexes (5-coordinate) would not be stable
under crystallization conditions. However, energy-
minimized refined structures were obtained, allowing
MOBCAL theoretical CCSs to be determined for com-
parison with the T-wave–derived values (Table 1).
In summary the experimentally derived T-wave
CCSs were compared with the MOBCAL-derived CCS
values (Table 1). It can be seen that the CCS calculations
obtained using MOBCAL are in excellent agreement
with experimentally derived values and show a similar
trend with the experimental data for the CCS measure-
ments obtained using IM.
Conclusion
Here we have shown for the first time that low-
molecular-weight isomeric ruthenium(II) terphenyl an-
ticancer complexes can be differentiated as a function of
their structures in the gas phase using ion mobility
spectrometry. Theoretical CCS values show a trend
similar to that of the experimentally derived data. The
drift times obtained for the m/z 427.1 species from a
mixture of complexes 2 and 1 and the mixture of
complexes 3 and 1 showed significant differences,
whereas similarities in the conformations of 2 and 3
render them more difficult to separate under the
present experimental conditions. The differences in
shape and mobility correlate with the reported differ-
ences in anticancer activity. Complexes 2 and 3 show
similar but reduced anticancer activity compared with
the more potent complex 1.
The CCSs of the three isomeric species were obtained
by calibration of the T-wave mobility device using
known CCS values of singly charged tryptic peptide
ions formed from an human hemoglobin digest. The
T-wave mobility-derived CCS measurements were in
excellent agreement with theory. The data reported
here show that ion mobility mass spectrometry can
provide quantitative data on the molecular shape and
mobility of candidate anticancer complexes and other
isomeric complexes, contributing to our understand-
ing of structure–activity relationships and to the drug
design process.
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